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Abstract
Purpose: A set of treatment planning strategies were designed and retrospectively implemented for locally advanced, non-small cell lung cancer
(NSCLC) patients in order to minimize cardiac dose without compromising target
coverage goals.
Methods: Retrospective analysis was performed for 20 NSCLC patients prescribed to 60–66 Gy that received a mean heart dose (MHD) ≥10 Gy. Three
planning approaches were designed and implemented. The first was a multiisocentric (MI) volume-modulated arc therapy (VMAT) approach (HEART_MI)
with one isocenter located within the tumor and the second chosen up to 10 cm
away longitudinally. The second was a noncoplanar (NCP) VMAT approach
(HEART_NCP) utilizing up to three large couch angles and a standard arc at
couch 0. The final planning strategy took a mixed approach (HEART_HYBRID)
utilizing the HEART_NCP strategy for two thirds of the treatment combined
with a plan utilizing a pair of opposite-opposed gantry angles for the remaining
treatments. Investigational plans were compared to original plans using dose–
volume histogram metrics such as organ volume receiving greater than x Gy
(Vx) or mean dose (Dmean).
Results: Although there was a small but statistically significant decrease in
internal target volume coverage for HEART_MI plans and, conversely, a statistically significant increase for HEART_NCP plans, all generated plans met
physician-prescribed target constraints. For heart dose, there were statistically significant decreases in all heart metrics and particularly MHD for the
HEART_MI (9.8 vs. 15.4 Gy [p < 0.001], respectively), HEART_NCP (9.2 vs.
15.4 Gy [p < 0.001]), respectively), and HEART_HYBRID (7.9 vs. 15.4 Gy
[p < 0.001], respectively) strategies.
Conclusions: The strategy providing the best compromise between plan quality
and cardiac dose reduction was HEART_NCP, which produced MHD reductions
of 37.6% ± 12.9% (6.2 ± 3.4 Gy) relative to original plans. This strategy could
potentially reduce adverse cardiac events, leading to improved quality of life for
these patients.
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INTRODUCTION

Lung cancer is the leading cause of cancer death for
both men and women in the United States, and the
most common type of lung cancer is non-small cell
lung cancer (NSCLC), which comprises 80%–85% of all
lung cancer cases.1 Traditionally, radiotherapy with concurrent chemotherapy has played a critical role in the
treatment of patients with inoperable, locally advanced
NSCLC due in large part to the extent of lesion, age of
the patient, and other patient comorbidities.2 However,
the outlook for patients undergoing locally advanced
NSCLC treatments is poor with 5-year overall survival
rates hovering between 15% and ∼30%3,4 and little data
available about long-term survival rates. There have
been several avenues investigated to improve the outcomes for this population of patients with the most
significant efforts related to dose escalation. The Radiation Therapy Oncology Group (RTOG) 0617 trial was
designed in order to determine whether a 74-Gy dose
regimen would provide better survival outcomes than
the traditional 60-Gy dose regimen as well as to evaluate
the effectiveness when cetuximab was added to concurrent chemotherapy.5 It was found that the patients in the
74-Gy arm showed significantly worse overall survival
outcomes relative to patients in the 60-Gy arm (20.3 vs.
28.7 months).
One of the factors identified in multivariate analysis that could best explain the lower overall survival
results in the high dose group was cardiac dose, particularly Heart V5 (volume of the heart receiving ≥5 Gy)
and V30.3 Although the negative effects of high cardiac
dose are well understood and studied in other types of
radiotherapy such as in breast cancer,6–8 esophageal
cancer,9 and Hodgkins lymphoma,10,11 it has not been
well studied within the context of locally advanced,
NSCLC patients. This has historically been related to
the poor prognosis and short typical lifespans after
radiotherapy for this population of patients, which has
led to the focus on factors that present more acutely
and have been shown to have more of an immediate
effect on patient outcomes such as esophageal and
lung dose that could lead to esophagitis or radiationinduced pneumonitis.12 Therefore, cardiac dose has not
been as highly prioritized. For example, in the parameters for RTOG 0617, cardiac dose goals were quite
general in only recommending the use of constraints
such as <40 Gy to 100% of the heart.5
In the wake of the results from RTOG 0617, several groups have investigated whether the link between
cardiac dose and overall survival could be replicated
in independent groups. Although some studies,13 such
as the Phase III ESPATUE trial that considered the
effect of neoadjuvant chemotherapy followed by either
surgery or definitive radiotherapy,14 were not able to verify the link between cardiac dose and overall survival, a
series of retrospective single institution studies15–19 and

meta-analysis20 were able to support the link between
cardiac dose and the incidence of cardiac adverse
events. A retrospective study out of the University of
Michigan19 found that on multivariate analysis, the presences of preexisting cardiac disease and mean heart
dose (MHD) were found to be significantly related to the
incidence of Common Terminology Criteria for Adverse
Events21 grade 3 or higher cardiac adverse events.However, the incidence of disease progression (n = 71)
exceeded that of cardiac events. Therefore, the need for
cardiac sparing was illustrated, while also underscoring
that this cannot be done at the expense of sacrificing target coverage. In another retrospective study out
of the University of North Carolina,17 they found that
MHD was significantly associated with the incidence
of treatment-related future cardiac events, which had
reached greater than 10% of patients at 2 years. Likewise, in a study out of the Dana-Farber Cancer Institute
and Brigham and Women’s Hospital,15 MHD (>10 Gy
compared to ≤10 Gy) was significantly associated with
an increased risk of major adverse cardiac events and
all-cause mortality for a subset of patients. This connection between the increase of symptomatic cardiac
events and lower overall survival was investigated in a
Rutgers study18 that found after multivariate analysis
that MHD and baseline cardiac status were associated with an increased risk of symptomatic cardiac
events and that the incidences of symptomatic cardiac events were independently associated with overall
survival.
As the prognosis for locally advanced NSCLC patients
has improved with the introduction of new treatment
technologies such as intensity-modulated radiotherapy,
immunotherapy, and other targeted therapies,22 the
results of these trials have lent credence to the argument that it is increasingly important to consider the
effect of cardiac dose for these patients,while also maintaining a strong emphasis on neither sacrificing target
coverage nor significantly increasing lung doses. At minimum, this seems to be especially true within the context
of patients who have baseline cardiac disease prior to
radiotherapy. There is also strong evidence from secondary analysis of the RTOG 0617 trial that there exists
a correlation between cardiac dose–volume histogram
(DVH) metrics and quality of life (QOL) metrics after 1
year.23 There exists then a need to utilize strategies for
minimizing heart dose to a level that mitigates the risk
of cardiac adverse events. Therefore, we implemented
a set of three planning templates that could be used
for this patient population to determine their effectiveness at reducing cardiac dose relative to conventional
planning techniques for challenging cases. In this retrospective study, we evaluated the efficacy of these
treatment planning strategies at minimizing dose to the
heart without having to compromise target coverage.
Each of these planning strategies is compared for their
effectiveness at reducing cardiac dose and maintaining
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traditional target and organ-at-risk (OAR) (particularly
lung) dose levels relative to the original treatment plans.

2
2.1

METHODS
Patients

Retrospective analysis was performed for 20 locally
advanced, NSCLC patients (T3–T4, N0–N3). Using the
MHD threshold that correlated with an increased level
of major adverse cardiac events from the study by
Atkins et al.,15 patients were selected who had originally received MHD > 10 Gy in the original plans
that were used for the patients’ actual course of treatment. The patient population consisted of 7 men and
13 women with a median age of 70 years (range:
59–81) with either adenocarcinoma (n = 11) or squamous cell carcinoma (n = 9). Treatment site ranged
from 10 left-sided (6 lower lobe, 4 upper lobe), 8 rightsided (6 lower lobe, 1 upper lobe, and 1 middle lobe),
and 2 mediastinal lesions. All patients underwent radiotherapy using volume-modulated arc therapy (VMAT)
to a total dose of 60–66 Gy in 2 Gy per fraction
(30–33 fx).

2.2

CT acquisition

All patients underwent 4DCT simulation using Brilliance
Big Bore (Philips Health Care, Cleveland, OH) CT scanners to acquire phase-based 4DCT thorax images with
10 phases reconstructed. The following parameters
were used for scan acquisition: 120 kVp, 800 mA s,
512 × 512 in-plane image dimensions, 1.17 × 1.17 mm2
in-plane resolution,and 3-mm slice thickness.The phase
images were used to derive an average image that
was used for treatment planning and a maximum intensity projection image to aid in contouring. A motion
encompassing method was employed for target volume
generation using an internal target volume (ITV)-based
approach. Based on individual patient characteristics,
the expansion from the ITV to the PTV ranged from an
isotropic expansion of 0.5 cm on the low end to asymmetric expansions of 0.5 cm axially and 1–1.5 cm along
the cranial–caudal axis.

2.3

Treatment planning

Patients were treated using plans generated in the
Eclipse treatment planning system Version 15.6 (Varian Medical Systems/Siemens Healthineers, Palo Alto,
CA). Plans were generated for a Varian TrueBeam treatment machine using the photon optimizer. Plans used a
6-MV photon energy and utilized between two and four
coplanar VMAT beams as shown in Figure 1.

F I G U R E 1 Typical treatment planning methodology used for
original plans utilizing two coplanar arcs

The plans utilizing the investigational treatment planning strategies were generated by one certified medical
dosimetrist with 3-year planning experience and one
board certified medical physicist with 6 years of clinical experience. The planning strategies evaluated were
selected based on the ability to minimize geometric
overlap of the beam path and the contoured heart structure. Several different strategies were tested. Those
presented here showed the most promise at reducing cardiac dose and are deliverable. These techniques
were evaluated to determine which would perform best
and in what circumstances the others might provide
advantages. Plans used for patient treatments were
replanned with the same photon energy but incorporating the following planning strategies (see Figure 2)
intended to reduce heart dose, while maintaining target coverage and keeping OAR dose within constraints.
The first planning strategy was a multi-isocentric (MI)
VMAT approach (HEART_MI). The first isocenter is at
a standard location within the tumor, and the second
isocenter was chosen up to 10 cm inferiorly or superiorly to the original with the choice of distance among
isocenters based on patient anatomy. As demonstrated
in Figure 2a, this was done in order to minimize overlap of the beam by directing it above or below the heart
depending on the relative position of the lesion and
the heart. The distance chosen minimized the geometric overlap of the treatment field with the heart, and a
half beam block on the second arc was utilized to further reduce divergence of the beam into the heart. This
typically resulted in choosing the largest distance from
the initial isocenter possible with the constraint of the
10-cm limit typically due to the longitudinal extent of
the treatment planning CT. Only the two arcs were used
in order to maximize the reduction in cardiac dose. At
each isocenter, one or two coplanar arcs were utilized
for planning.
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F I G U R E 2 Proposed planning strategies: (a) HEART_MI strategy that utilizes two volume-modulated arc therapy (VMAT) arcs at two
isocenters with ∼10-cm difference along the Sup-Inf axis. (b) HEART_NCP strategy that utilizes a traditional VMAT arc at couch 0 along with
anterior arcs at up to three noncoplanar delivery angles, and (c) HEART_HYBRID approach that utilizes the HEART_NCP strategy for two thirds
of treatments and an opposite-opposed approach with beams that avoid overlapping the heart for the remaining one third

The second planning strategy was a noncoplanar
(NCP) VMAT approach (HEART_NCP) that utilized up
to three large couch angles (typically using either 30–
60–90- or 330–300–270-degree couch kicks depending
on the side of the lesion) in combination with a standard
arc at a couch angle of 0 degree (Figure 2b). Smallangled (typically around 45 degree) gantry arcs over the
anterior portion of the patients were used at the large
couch angles in order to avoid collisions between the
gantry and couch or patient. Just as with the HEART_MI
strategy, this strategy attempts to identify advantageous
angles for minimizing geometric overlap of the treatment
field with the heart, but by rotating the patient instead
of shifting the patient longitudinally. The final planning
strategy took a mixed approach (HEART_HYBRID) that
utilized the HEART_NCP strategy for two thirds (20–
22 fx) of the treatment combined with a plan that utilized
a pair of opposite-opposed gantry angles for the remaining one third of patient treatments (10–11 fx) (Figure 2c).
The opposite-opposed gantry angles were selected to
minimize overlap of the beams with the heart in order
to further push the dose reduction to the heart, and the
proportion of each plan that constituted the total treatment was determined in preliminary evaluation in order
to maintain an acceptable level of conformality.
In this study, the normal tissue constraints from protocol RTOG 1106–669724 were utilized, and target
criterion was 60–66 Gy (2 Gy f xn) as requested in dose

prescriptions. Typical criteria listed include the percent
volume of a structure receiving greater than x Gy dose
(VxGy) and the max dose in gray (Gy) to x volume
of a structure (Dx%). Target criteria used in this evaluation included ITV and PTV D95% and Dmax, which
were parameters listed in the physician’s prescription for
assessing coverage and homogeneity, as well as D98%
to assess the near minimum dose to the targets. The full
lists of normal tissue constraints used for this study are
listed in Table 2. Listed constraints are taken from institutional prescription constraints that are based on RTOG
1106. Additionally, V5Gy of the heart was evaluated
due to the significance of the correlation between V5Gy
and cardiac toxicity in several studies (including RTOG
0617). The optimization constraints (including hard and
soft constraints) from the original plans were carried
over to the new plans. Dose conformity to and fall-off
outside the PTV was also assessed using the conformity
index (CI) determined in two ways. We used the RTOG
defined as the ratio between the volume covered by the
reference isodose and the target volume. For this study,
the CI was calculated by evaluating the conformity of the
95% prescription isodose (CI95 ) as in the RTOG convention (CI95 = PTV volume/95% prescription isodose),25
and also using Paddick’s CI formulation that uses the
prescription isodose (CIRx ) as the reference isodose and
takes into account the amount of overlap of the reference isodose and the target volume (CIRx = [overlap of
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Comparison of the original target dosimetric values with those of HEART_MI, HEART_NCP, and HEART_HYBRID

Targets

Original
plan
Mean
(StDev)

HEART_MI
Mean
(StDev)

Difference

HEART_NCP
Mean
(StDev)

Difference

HEART_HYBRID
Mean
(StDev)
Difference

PTV

D95 (Gy)

60.1 (4.4)

60.0 (3.9)

−0.1 (1.5)

60.9 (4.0)

0.8 (1.3)

60.1 (3.9)

−0.0 (1.4)

PTV

D98 (Gy)

59.0 (4.5)

59.0 (3.9)

−0.0 (1.7)

59.8 (4.0)

0.8 (1.4)

59.0 (3.9)

−0.1 (1.6)

PTV

Dmax (Gy)

67.3 (4.6)

67.6 (4.6)

0.2 (1.7)

67.6 (4.5)

67.1 (4.4)

−0.2 (2.3)

PTV

CI95

1.18 (0.8)

1.09 (0.1)

−0.9 (0.8)

1.11 (0.11)

−0.07 (0.8)

1.12 (0.13)

−0.06 (0.8)

PTV

CIRx

0.52 (0.21)

0.41 (0.19)

−0.12 (0.2)

0.73 (0.08)

0.21 (0.2)

0.52 (0.16)

ITV

D95 (Gy)

62.1 (4.3)

61.3 (4.1)

−0.8 (1.1)

63.0 (4.0)

0.9 (1.9)

62.0 (4.0)

ITV

D98 (Gy)

61.7 (4.2)

60.9 (4.1)

−0.8 (1.1)

62.5 (4.0)

0.8 (1.4)

61.5 (4.0)

−0.2 (1.4)

ITV

Dmax (Gy)

66.8 (4.6)

66.6 (4.4)

−0.2 (1.7)

66.6 (4.6)

−0.2 (1.1)

66.7 (4.4)

−0.1 (1.9)

0.3 (1.5)

0 (0.21)
−0.1 (1.3)

Note: Mean and standard deviation for each constraint and planning strategy are given as well as the mean and standard deviation of the absolute difference between
each novel planning strategy and the original plan values. Statistically significant values are bolded and italicized.
Abbreviation: ITV, internal target volume.

PTV and prescription isodose]2 /[PTV volume × volume
of prescription isodose]).26 Optimization objectives were
kept the same among all treatment strategies except for
the heart optimization objectives, which were adjusted
in order to achieve the best heart dose while maintaining plan quality. Dosimetric differences between each
of the trial planning strategies was compared to the
original plan. Dose distributions generated using the various planning strategies were reviewed by a radiation
oncologist to assess the acceptability of the plan apart
from simple DVH metrics. Statistical significance of the
change in dosimetric measurements between each of
the trial planning strategies and the original plan was
assessed using a paired t-test with a significance level
of p = 0.05.

3

RESULTS

Tables 1 and 2 provide a comparison of the dosimetric values for each of the different planning strategies
and for the original plan for targets and OARs, respectively. The percentage difference between the value for
the original plan and that of the alternative planning
strategies is also listed in the table. Every generated
plan met the original target constraints specified in the
physicians’ prescriptions. As can be seen in Table 1,
there are also no statistically significant differences in
PTV coverage between any of the experimental strategies and the original plan aside from a small increase
in D98 coverage for the HEART_NCP strategy (59.8 vs.
59.0 Gy, p = 0.03). For the ITV, however, there were small
decreases in D95 (61.3 vs. 62.1 Gy [p < 0.001]) and
D98 (60.9 vs. 61.7 Gy [p < 0.001]) for the HEART_MI
strategy. This is also reflected in that both CI95 (1.09
for HEART_MI vs. 1.18, respectively) and CIRx (0.41 vs.
0.52, respectively) scores are lower compared to the
original plan as seen in Table 1, indicating that, although

these plans were more conformal with respect to the
95% isodose (less overcoverage), there was a sharper
falloff after achieving the prescription constraint, leading to the decrease in D98 and lower coverage of the
higher prescription isodose. This was largely caused by
difficulty in achieving coverage on the side of the target
in the cranial–caudal axis opposite the shifted isocenter.
By contrast, there were small increases in D95 (63.0 vs.
62.1 Gy [p = 0.04]) and D98 (62.5 vs. 61.7 Gy [p = 0.02])
for the HEART_NCP strategy. In this case, the NCP
delivery angles included more advantageous treatment
directions that made it possible to more readily achieve
target coverage goals. As seen in Table 1, this resulted in
a more conformal plan in terms of CI95 , where there was
less over-coverage of the 95% isodose compared to the
original plan (1.11 vs. 1.18, respectively), whereas the
CIRx values also reflected better coverage and conformity of the prescription isodose (0.73 vs 0.56). Although
the target coverage differences were statistically significant for D95 and D98, they are generally much less than
1 Gy over the total treatment course (60–66 Gy) and
therefore unlikely to be clinically significant.
The reduction in cardiac dose is clearly displayed in
Table 2. The dosimetric measurements for the heart
are listed at the top of Table 2 where there were statistically significant decreases in Heart V5, V30, V50,
and mean dose for the HEART_MI (54.8% vs. 76.5%
[p < 0.001], 6.2% vs. 13.1% [p < 0.001], 2.3% vs. 3.3%
[p = 0.01], and 9.8 vs. 15.4 Gy [p < 0.001], respectively), HEART_NCP (52.0% vs. 76.5% [p < 0.001],
5.8% vs. 13.1% [p < 0.001], 2.2% vs. 3.3% [p = 0.02],
and 9.2 vs. 15.4 Gy [p < 0.001], respectively), and
HEART_HYBRID (42.6% vs. 76.5% [p < 0.001], 5.0% vs.
13.1% [p < 0.001], 2.3% vs. 3.3% [p = 0.02], and 7.9 vs.
15.4 Gy [p < 0.001], respectively) strategies. Additionally, there was also a statistically significant decrease
in Heart max dose (62.3 vs. 64.2 Gy, p = 0.02) for
the HEART_HYBRID strategy. Particularly of note due

15269914, 0, Downloaded from https://aapm.onlinelibrary.wiley.com/doi/10.1002/acm2.13784 by Readcube (Labtiva Inc.), Wiley Online Library on [30/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

KIM ET AL.

TA B L E 2

KIM ET AL.

Comparison of the original organ-at-risk (OAR) dosimetric values with those of HEART_MI, HEART_NCP, and HEART_HYBRID

OARs
⇐

Heart

D0.03cm3

Heart

V5Gy (%)

Heart

V30Gy (%)

⇐

Heart

V50Gy (%)

⇐

Heart

Dmean (Gy)

Lungs-ITV

V20Gy (%)

Lungs-ITV
Lungs-ITV

(Gy)

HEART_MI
Mean
(StDev)

Difference
−0.5 (3.3)

HEART_NCP
Mean
(StDev)
Difference
−0.3 (3.9)

63.7 (6.8)
54.8 (14.9)

50

13.1 (7.1)

6.2 (3.9)

−6.9 (6.1)

5.8 (3.2)

−7.3 (6.0)

5.0 (2.9)

−8.1 (5.8)

25

3.3 (2.8)

2.3 (2.0)

−1.0 (1.7)

2.2 (1.9)

−1.1 (1.7)

2.3 (2.0)

−1.0 (1.7)

⇐

20

15.4 (4.1)

9.8 (2.0)

−5.6 (3.4)

9.2 (1.9)

−6.2 (3.4)

7.9 (1.5)

−7.5 (3.4)

⇐

35

24.6 (7.2)

26.2 (8.0)

1.6 (3.0)

25.9 (7.0)

1.4 (3.5)

27.9 (9.1)

3.4 (6.1)

V5Gy (%)

⇐

65

62.1 (7.9)

64.0 (12.1)

2.0 (9.2)

64.6 (12.9)

2.5 (10.7) 59.3 (14.8)

Dmean (Gy)

⇐

20

14.4 (3.1)

14.8 (3.3)

0.4 (1.4)

14.8 (3.2)

0.3 (1.4)

Esophagus

D2cm3 (Gy)

Esophagus

Dmean (Gy)

Spinal cord

D0.03cm3 (Gy)

(Gy)

−21.6 (11.6) 52.0 (11.6)

62.3 (5.9)

−1.9 (3.2)

64.2 (6.9)

Esophagus

63.9 (6.6)

HEART_HYBRID
Mean
(StDev)
Difference

76.5 (19.9)

D0.03cm3

70

Original
plan
Mean
(StDev)

−24.4 (15.1) 42.6 (8.3)

14.5 (3.7)

−33.9 (17.6)

−2.8 (13.1)
0.1 (3.3)

⇐

68

52.7 (16.1)

54.8 (14.0)

2.1 (4.6)

54.4 (15.7)

1.7 (4.4)

54.1 (15.0)

1.4 (6.7)

⇐

63

44.5 (15.8)

45.8 (14.7)

1.3 (5.3)

44.7 (16.1)

0.2 (5.7)

45.4 (16.8)

0.9 (8.6)

⇐

34

20.6 (9.8)

20.5 (9.3)

−0.2 (4.6)

19.9 (9.7)

−0.8 (4.6)

19.9 (10.7)

−0.7 (5.7)

⇐

45

32.3 (10.0)

34.0 (7.3)

1.7 (5.5)

31.4 (7.8)

−0.9 (5.0)

40.0 (4.9)

7.7 (6.9)

Note: Mean and standard deviation for each constraint and planning strategy are given as well as the mean and standard deviation of the absolute difference between
each novel planning strategy and the original plan values. Statistically significant values are bolded and italicized.
Abbreviation: ITV, internal target volume.

F I G U R E 3 Graph showing the % volume of the heart receiving
5 Gy (V5Gy) for the original plan (blue) for each patient overlaid with
the corresponding V5Gy for the HEART_MI (red), HEART_NCP
(gray), and HEART_HYBRID (yellow) strategies

to the correlation between these factors and cardiac
adverse events, Figures 3–5 provide a comparison of
the reduction in Heart V5Gy, V30 Gy, and MHD, respectively, for each patient. These were selected due to their
importance in correlating with cardiac adverse events in
previous studies. In those figures, original plan dosimetric values in blue are overlaid with the values for each of
the alternative planning strategies to picture the reduction in value per patient. Using the HEART_MI strategy,
MHD was reduced below 10 Gy for 12 of the patients,
whereas the number for HEART_NCP was 16 patients
and HEART_HYBRID was 18 patients.
For the non-heart OARs, there were no significant
differences in esophagus or lung dose aside from an
increase in lung V20 for HEART_MI (26.2% vs. 24.6%,

F I G U R E 4 Graph showing the % volume of the heart receiving
30 Gy (V30Gy) for the original plan (blue) for each patient overlaid
with the corresponding V30Gy for the HEART_MI (red),
HEART_NCP (gray), and HEART_HYBRID (yellow) strategies

F I G U R E 5 Graph showing the mean heart dose (MHD) for the
original plan (blue) for each patient overlaid with the corresponding
MHD for the HEART_MI (red), HEART_NCP (gray), and
HEART_HYBRID (yellow) strategies
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p = 0.03) and HEART_HYBRID (27.9% vs. 24.6%,
p = 0.02) that were both a result of an increased
overlap of the beam path and lung due to the larger
angles used to minimize heart overlap. Similarly, there
were no significant differences in the maximum dose to
the spinal cord aside from the increase when using the
HEART_HYBRID strategy (32.3 vs. 40.0 Gy, p < 0.001),
which was a result of the contribution of the portion
of the treatment that utilized an opposite-opposed
beam arrangement that often overlapped the spinal
cord to find an optimal angle for avoiding the heart.
Overall, average monitor units (MUs) for the original
plan was 513.6 ± 117.6 MU, whereas the average was
705.2 ± 89.7, 623.6 ± 102.6, and 623.6 ± 102.6 MU
(NCP portion)/291.0 ± 53.4 MU (opposite-opposed
portion) for the HEART_MI, HEART_NCP, and
HEART_HYBRID strategies, respectively.

4

DISCUSSION

In this study, three planning strategies were retrospectively implemented in order to assess their feasibility at
reducing dose to the heart and ultimately cardiac toxicity. Each of the planning strategies was able to achieve
reduced heart dose while maintaining target coverage
and meeting listed OAR constraints, though with tradeoffs that were unique to each of them. The MI approach
(HEART_MI) exhibited the smallest dose reduction but
was able to reduce the mean dose below 10 Gy for
over half of the patients. Due to the geometry of the
approach, there was a small drop in target coverage
typically at the superior end of the lesion (opposite the
shifted isocenter), and there was a greater amount of
overlap of the beam with the lung, and therefore, a
higher lung V20, though within the listed constraints.
Overall, the HEART_NCP plan showed the best conformity even relative to the original plans, which could be
attributed to providing advantageous treatment angles
to improve conformity. As expected, this did lead to an
increase in the low dose spread (V5Gy) in the anterior
region of the patient,which can be observed in the larger
lung V5 when using the HEART_NCP strategy (2.5%
increase over original plans). For the HEART_MI plans,
the conformity was similar to the original plan overall.
However, there was a bit of an increase in the spread of
dose superior and inferior to the target due to the angle
of the off -isocenter arc, partially contributing to lower
CIRx scores for this patient set. In HEART_HYBRID
plans, the opposite-opposed portion of the plan led to a
stretching of the dose along the angle of those beams
and provided the greatest challenge in terms of clinical acceptability. The strategy that showed the greatest
amount of cardiac dose reduction was the mixed plan
(HEART_HYBRID), which showed significant decrease
in cardiac dose for every metric tested as well as reducing the MHD below 10 Gy for all but two patients.
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However, particularly because of the contribution of the
portion of the treatment that used an opposite-opposed
beam arrangement, this led to a higher V20 and spinal
cord dose than in the original plans. This was due to
the necessity of choosing angles that minimized overlap with the heart which usually led to beam paths
that passed through the contralateral lung and directly
through the spinal cord.
The planning strategy that seemed to exhibit the optimal reduction in dose to the heart without leading to
significant differences for other OARs was the NCP
strategy (HEART_NCP). However, this planning strategy required a greater amount of complexity relative to
alternative methods both in terms of treatment planning
and treatment setup and delivery. This was reflected in
the average increase of about 100 MU (or 20%) relative to the patients’ original plans. Additionally, the care
taken to avoid collisions of the gantry plus the increased
number of couch rotations during treatment would put
a greater strain on departmental resources. As mentioned earlier, MHD was highly dependent on volume
and length as well as distance of the lesion from the
target. Overall, it appeared that HEART_NCP strategy
provided the best conformity as reflected in the CI95 and
CIRx scores while also providing a significant level of
cardiac dose reduction. However, for those lesions closest to the heart, extending along the length of the heart,
and where there is room for compromise on the plan
conformity, the HEART_HYBRID strategy can provide a
level of cardiac dose sparing that the other two strategies struggle with. The HEART_MI strategy performed
best for smaller lesions where there was a separation
longitudinally between the lesion and the heart as in
Patient 17.
Not every patient may benefit from these types of nonstandard strategies to minimize cardiac dose. Patients
with lesions who only have a small portion may see only
minimal dosimetric improvement using these strategies.
In this study, Patient 13 showed the smallest dose reduction to the heart with MHD only decreasing in the range
from 0.4 Gy using the HEART_NCP strategy to 1.8 Gy
using the HEART_MI approach. In that case, the bulk
of the lesion was located superior to the heart (∼60%),
and the high MHD was driven by that part of the PTV
that directly overlapped or abutted the heart and so
had minimal potential for improvement without sacrificing target coverage. In this study, patients who received
an MHD greater than 10 Gy were selected based on
several studies that indicated that an MHD was significantly correlated with an increase in the level of cardiac
events,15,17,18 and that 10 Gy could be used as a threshold above which, there was a higher risk of cardiac
adverse events.15 However, several clinical prognostic
factors could be utilized to identify patients who may
benefit from a more aggressive approach for reducing
cardiac dose prior to planning. As mentioned previously, a significant correlation between the presence of
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preexisting heart conditions and an increase in cardiac
adverse events has occurred in several studies.15,17–19
Patients who exceeded this threshold tended to have
larger PTVs with a mean volume greater than 400 cm3
(mean: 415.3 cm3 [range: 115.83–1184.85 cm3 ]) with
mediastinal invasion in the anterior and middle regions
of the inferior mediastinum. For our patient set, although
no patients with PTV volumes less than 100 cm3
exceeded the threshold, patients with PTV volumes
between 100 and 200 cm3 exceeded the threshold only
23.2% of the time, and 51.8% of patients with PTV volumes greater than 300 cm3 exceeded the threshold.
PTV volume and location were the two biggest factors that led to excessive cardiac dose for this set of
patients, and these two factors could be used as a guide
to determine which patients are at highest risk of having excessive cardiac dose. Therefore, the patients who
would be expected to have the most benefit are those
patients with a higher risk profile due to a combination
of clinical factors such as preexisting cardiac disease
and dosimetric factors such as the likelihood of a high
cardiac dose as a result of size and location of tumor.
Although this paper focuses on the potential benefit
that could be derived from using tools that exist within
the current treatment planning framework, there exists
research into further methods to reduce dose using
artificial intelligence–based strategies that have shown
promise for finding the optimal solution for mitigating
OAR doses. Multiple methods have been proposed for
utilizing machine learning to improve dosimetric results
in radiotherapy through dose mimicking in head and
neck patients,27 generating optimal fluence maps that
can be imported into the treatment planning system for
dose calculation for prostate patients,28 and relevantly,
for reducing heart dose in lung cancer patients using
a machine-learning approach for assessing trade-offs
between lung and cardiac toxicity during planning.29 In
this last study, nearly 40% of patients had predicted
plans that exhibited mean dose reductions of >4 Gy in
MHD. This is a promising area of research, and there
exists a great deal of potential in utilizing a machinelearning guided method to further reduce cardiac dose
and ultimately toxicity in this population of patients.

5

CONCLUSION

Three planning strategies were introduced that were
able to reduce the cardiac dose, while maintaining
target coverage compared to the conventional planning
strategy and to maintain OAR doses within acceptable
levels. The strategy that provided the best compromise
between plan quality and cardiac dose reduction utilized
large NCP anterior arcs and produced MHD reductions
of 37.6% ± 12.9% (6.2 ± 3.4 Gy) relative to original
plans. This strategy could be implemented for a set
of patients who have been identified as higher risk

for cardiac adverse events based on clinical or other
prognostic factors, which has the potential to reduce
adverse cardiac events and improve the QOL for this
subset of patients.
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